AstraZeneca Scores 'Voucher' On Wellstat's Xuriden Approval

The FDA's approval on Sept. 4 of Wellstat Therapeutics' hereditary orotic aciduria (HOA) treatment Xuriden (uridine triacetate) means AstraZeneca has gained a coveted rare pediatric disease priority review voucher – a deal the two firms made last year, long before the so-called golden tickets were being sold for hundreds of millions of dollars.